Quick Summary

Shatavari (Asparagus racemosus) is an Ayurvedic medicinal plant traditionally used to support women’s reproductive health and overall well-being. Contemporary clinical studies suggest potential benefits in sexual health for women, management of menopausal symptoms, male fertility, and as an adjunct in cancer care. It contains bioactive steroidal saponins (shatavarins) with possible adaptogenic and estrogenic effects. While clinical evidence is emerging, it remains limited, and more well-designed trials are needed to confirm efficacy and safety.

What is it

Shatavari is a climbing herb native to the Indian subcontinent, often used in traditional Ayurvedic medicine. It is known for its root extract that contains steroidal saponins believed to contribute to its therapeutic potential. The plant is valued for its effects on hormonal balance, reproduction, and general vitality.

Traditional Uses

  • Supporting women’s reproductive and sexual health
  • Promoting lactation (galactagogue)
  • Alleviating menopausal symptoms
  • Enhancing overall strength and vitality
  • Improving digestion and immune health (in Ayurveda)

Active Compounds

Shatavari contains bioactive steroidal saponins known as shatavarins. These compounds have shown potential adaptogenic and estrogenic properties based on preclinical and in silico studies. Other phytochemicals may contribute to its pharmacological profile, although the primary focus remains on shatavarins.

Potential Benefits with Evidence Levels

  • Women’s Sexual Health (Human clinical evidence): A randomized, double-blind, placebo-controlled study found that Shatavari root extract, alone or combined with Ashwagandha, improved female sexual function aspects including arousal, lubrication, orgasm, satisfaction, and distress scales over 8 weeks with good tolerability.
  • Menopausal Symptoms (Human clinical evidence): A double-blind, multicenter randomized controlled trial demonstrated significant reduction in menopausal symptoms such as hot flashes, night sweats, insomnia, anxiety, vaginal dryness, and loss of libido, improving quality of life without significant adverse events.
  • Male Infertility (Low Sperm Count) (Human clinical evidence): In a 90-day randomized, placebo-controlled trial, a polyherbal formulation containing Shatavari was associated with significant improvements in sperm count, motility, serum testosterone, and sexual health parameters.
  • Cancer Supportive Care (Human clinical evidence, systematic review): A systematic review of clinical studies involving Asparagus officinalis products (including Shatavari) alongside chemotherapy suggested improvements in survival, response rates, quality of life, and immune function, though evidence certainty was low and further research is necessary.
  • Muscular Strength and Endurance (Human clinical evidence): An 8-week bench press training study with 500 mg/day Asparagus racemosus supplementation indicated improved muscular strength and endurance compared to placebo in recreationally trained men.
  • Adaptogenic and Estrogenic Effects (Preclinical and in silico evidence): Isolation studies identified shatavarins as steroidal saponins with predicted estrogen receptor binding and adaptogenic potential, supporting traditional hormone-related uses.

Side Effects

Shatavari formulations are generally reported as safe and well tolerated in clinical studies. Minor and infrequent adverse effects have been noted, none severe or requiring intervention. Some minor complaints mirror those seen with other herbal galactagogues. Long-term safety data remain limited.

Drug Interactions

No direct clinical evidence currently exists regarding drug interactions with Shatavari. However, due to its bioactive phytochemicals, potential interactions cannot be ruled out, especially with conventional medications such as chemotherapy agents or hormone therapies. Further research is required to clarify possible herb-drug interactions.

Who Should Avoid It

Specific contraindications are not clearly established for Shatavari. Caution is advised for individuals with hormone-sensitive conditions due to its potential estrogenic activity, although direct evidence is lacking. Pregnant and breastfeeding women should use Shatavari cautiously and under medical supervision because of limited safety data.

Evidence Limitations

Most clinical studies on Shatavari are limited by small sample sizes, short durations, varied formulations, and lack of standardized extracts, resulting in low certainty of evidence. Larger, well-designed, placebo-controlled trials with standardized dosing and longer follow-up are needed to verify efficacy, safety, and optimal use. Preclinical and computational studies suggest possible mechanisms but require validation in clinical settings.

References

  • Ademola J, Mahajan S, Srivathsan M, Langade D. Effects of Shatavari (Asparagus racemosus) Root Extract on Sexual Wellness in Women: Findings from a Prospective, Randomized, Double-Blind, Three-Arm, Parallel-Group, Placebo-Controlled Study. 2026. PMID: 41710148
  • Gudise VS, Dasari MP, Kuricheti SSK. Efficacy and Safety of Shatavari Root Extract for the Management of Menopausal Symptoms: A Double-Blind, Multicenter, Randomized Controlled Trial. 2024. PMID: 38725785
  • Kolsure P, Kolhe S, Dev A, Shintre SS, Dhavale SG, Kuber V, Padmanabhan S. Efficacy and Safety of Polyherbal Formulation in Low Sperm Count Participants: A Randomized, Multicenter, Double-Blinded, Placebo-Controlled, Interventional Study. 2025. PMID: 41527658
  • Shen C, Wu XT, Wang XF, Wang ZJ, Tian ZY, Robinson N, Liu JP. Asparagus officinalis potentially supports cancer care: a systematic review of randomized and non-randomized clinical studies. 2026. PMID: 41909047
  • D C D, Girme A, Salvankar K, Chinchansure A, Ranjan R, N L YK, R EJ, Mundkinajeddu D. Scale-Up Isolation of High-Purity Shatavarins from Asparagus racemosus via Flash Chromatography with Bioavailability and Pharmacological Insights. 2026. PMID: 41970898
  • Abhyankar M, Kadam D, Reddy PR, Siddiqui MZ, Ratheesh M, Jagmag T, Tilwani J. The Efficacy and Safety of Imusil® Tablets in the Treatment of Adult Patients With Mild COVID-19: A Prospective, Randomized, Multicenter, Open-Label Study. 2023. PMID: 37051002

Last Reviewed

June 2024

Informational Disclaimer: This page is for educational purposes only and does not provide medical advice. The information provided here should not be used to diagnose or treat health problems or diseases. Always consult a qualified healthcare professional before starting any new supplement or herbal treatment, especially if you are pregnant, breastfeeding, have existing health conditions, or are taking other medications.